In this context, targeting the MCFA receptor GPR84 is quite appealing, as it might represent a more NAFLD-specific pathway for recruiting inflammatory and fibrogenic macrophages to NASH livers. Here, GPR84 is linked to metabolic dysfunction-associated steatotic liver disease.